Lampang Cancer Hospital and AstraZeneca Thailand announced a strategic collaboration to improve cancer treatment and patient care through advanced medical technology and innovation. The initiative aims to enhance early-stage cancer screening and diagnosis, increasing long-term survival rates for patients. A pilot project has been launched to improve lung cancer care, support international oncology research, and establish a comprehensive referral network for timely treatment.
The partnership was formalized on July 22, 2025, with a Memorandum of Understanding signed by Dr. Rawin Ingsirorat, Director of Lampang Cancer Hospital, and Mr. Roman Ramos, President of AstraZeneca Thailand and Frontier Markets. The signing ceremony was attended by Dr. Taweesin Visanuyothin, Director-General of the Department of Medical Services, and Flt. Lt. (Dr.) Somchai Thanasitthichai, Director of the National Cancer Institute.
The collaboration focuses on public awareness, early-stage screening, and strengthening multidisciplinary teams to provide care aligned with international standards. AI-assisted chest X-ray technology will support accurate lung cancer detection, and a referral network will ensure high-risk patients receive timely treatment.
Officials emphasized that cancer remains a major public health challenge in Thailand, with over 140,000 new cases and approximately 83,000 deaths annually. The initiative seeks to improve early detection, deliver personalized treatment, and enhance patient outcomes while contributing to the long-term sustainability of Thailand’s healthcare system. The pilot project is intended as a model for a national lung cancer care program and demonstrates the integration of technology and innovation into patient-centered oncology services.
(Source: AstraZeneca)
